Company / Revenue
Theravance Biopharma, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$107.5M
FY2025
5-year range
$55.3M / $107.5M
FY2021-FY2025
Trend
+66.9%
vs FY2024
Sector context
#106 of 155
Health Care
What the data says
At $107M, Theravance Biopharma, Inc.'s revenue ranks #106 of 155 in the Health Care sector. Revenue has fluctuated over the past 10 years, ranging from $3M in FY2017 to $107M in FY2025.
Based on SEC 10-K filings.
$107M in FY2025 with a 5-year CAGR of +8.4%.
Improved from $57M to $107M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +14.4%
- 5-Year CAGR
- +8.4%
- 10-Year CAGR
- -
Sector benchmark
#106 of 155 in Health CareTop 68% of 155This company $107.5M Sector average $4.5B
▼
-97.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.4%, indicating consistent growth.
- In FY2025, revenue increased 66.9% year-over-year.
- Ranks #106 out of 155 companies in the Health Care sector.
- Lowest revenue in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $107.5M | +66.9% |
| FY2024 | $64.4M | +12.1% |
| FY2023 | $57.4M | -20.1% |
| FY2022 | $71.9M | +29.9% |
| FY2021 | $55.3M | -23.0% |
| FY2020 | $71.9M | +367.0% |
| FY2019 | $15.4M | -68.4% |
| FY2018 | $48.6M | +1475.9% |
| FY2017 | $3.1M | -93.7% |
| FY2016 | $48.6M | +21425.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026